肿瘤药学2019，Vol.9Issue(3)：380-383,4.DOI:10.3969/j.issn.2095-1264.2019.03.06
EGFR-TKI获得性耐药相关T790M突变与非小细胞肺癌上皮间质转化和IGF-1R的相关性研究★
Correlation of EGFR-TKI Acquired Resistance-Related T790M Mutation with Epithelial Mesenchymal Transition and IGF-1R in NSCLC ★
摘要
Abstract
Objective To investigate the relationship of acquired resistance-related T790M mutation to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with the epithelial-mesenchymal transition (EMT) and insulin-like growth factor type 1 receptor (IGF-1R). Methods Sixty-four patients with advanced non-small cell lung cancer (NSCLC) who were treated with EGFR-TKI and acquired drug resistance in our hospital during March 2014 and April 2015 were selected. Then they were followed-up after divided into mutation group and non-mutation group according to T790M mutation. The expression of EMT marker genes and IGF-1R pathway molecules in the lesion were measured. Results The progression-free survival and total survival time of the mutation group were shorter than those of the non-mutation group. The mRNA expres-sion levels of Vimentin, N-cadherin, IGF-1R, PI3K, AKT and ERK in lesions of mutation group were higher than those of the non-mutation group. The mRNA expression of E-cadherin in lesions of mutation group was lower than that of the non-mutation group. Conclusion Acquired resistance-related T790M mutation to EGFR-TKI can aggravate the degree of EMT and the activation of IGF-1R pathway in tumor lesions.关键词
非小细胞肺癌/表皮生长因子受体-酪氨酸激酶抑制剂/T790M突变/上皮间质转化/胰岛素样生长因子1型受体Key words
Non-small cell lung cancer/Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI)/T790M mutation/Epithelial-mesenchymal transition (EMT)/Insulin-like growth factor-1 receptor (IGF-1R)分类
医药卫生引用本文复制引用
顾国民,卢素琼,展翼翼,朱晓丹,刘春玲..EGFR-TKI获得性耐药相关T790M突变与非小细胞肺癌上皮间质转化和IGF-1R的相关性研究★[J].肿瘤药学,2019,9(3):380-383,4.基金项目
新疆医科大学科研创新基金(XYDCX201553). （XYDCX201553）
